Krystal Biotech Authorizes Up To $400 Million Buyback As Net Income Falls To $63.1 Million

The gene-therapy maker's operating income rose to $71.1 million, but a year-earlier tax benefit did not repeat.

Share
Krystal Biotech Authorizes Up To $400 Million Buyback As Net Income Falls To $63.1 Million

Krystal Biotech, which makes the topical gene therapy VYJUVEK for a rare skin disease, said Monday its board authorized a $400 million share repurchase program that it expects to carry out opportunistically over the next two years. The announcement came with third-quarter results in which operating income climbed while net income fell.

Buyback terms

The program has no expiration date and does not obligate Krystal to buy any amount of stock, and the company can modify, suspend or end it at any time, the company said. Purchases can be made on the open market, in private deals or through trading plans.

CEO Krish S. Krishnan said the plan "reflects our confidence in Krystal's long-term growth prospects and our commitment to disciplined capital allocation." Cash and investments stood at $1.2 billion on September 30.

Profit slips on a tax swing

VYJUVEK net product revenue was $127.3 million in the third quarter, up 30% from a year earlier, with a gross margin of 94%. Sales since launch reached $1.1 billion, the company said.

Income from operations rose to $71.1 million from $41.4 million. Net income fell to $63.1 million, or $2.05 per diluted share, from $79.4 million, or $2.66, because Krystal booked a $17.1 million tax expense against a $31.4 million tax benefit in the year-earlier quarter.

For the first nine months, net income rose to $173.8 million from $153.4 million, on product revenue of $362.9 million versus $282.0 million. For 2026, Krystal guided to non-GAAP combined research-and-development and selling and administrative spending of $155.0 million to $165.0 million, a measure that excludes stock-based compensation.

Pipeline and launch calendar

Krystal sells VYJUVEK, approved in the United States, Europe and Japan, and has secured over 760 U.S. reimbursement approvals. Pricing talks are complete in Germany and Italy, with an Italian launch expected in early 2027, and a decision in Spain is expected later this year.

Interim results from the KB111 study in Hailey-Hailey disease are expected before year end. Enrollment in the EMERALD-1 eye study has run slower than anticipated, and the company now expects top-line results in 2027.

Krystal said it expects to report interim KB111 results before the end of the year.

Sources